Sermonix Launches Phase 2 Trial Testing Lasofoxifene in Advanced Breast Cancer Patients with ER Mutations

Sermonix Launches Phase 2 Trial Testing Lasofoxifene in Advanced Breast Cancer Patients with ER Mutations
Sermonix is launching a Phase 2 trial to determine if its lead investigational medicine lasofoxifene is better than Faslodex (fulvestrant) at delaying disease progression or death in breast cancer patients who have a mutation in the estrogen receptor gene ESR1. The open-label, randomized, multicenter trial will include 100 postmenopausal women with locally advanced or metastatic ER-positive/HER2-negative breast cancer. Recruitment will take place across 27 sites in the U.S. “Sermonix is developing lasofoxifene as a personalized medicine treatment for patients with ER+ metastatic breast cancer that have progressed after endocrine and other therapies,” David Portman, Sermonix's CEO, said in a press release. “We look forward to seeing how it performs in the Phase 2 trial versus fulvestrant.” Therapies targeting the estrogen receptor (ER), such as Faslodex, are a mainstay in the treatment of ER-positive breast cancer. But despite initial responses, a large number of patients becomes resistant to treatment by acquiring ER mutations. Lasofoxifene is a selective estrogen receptor modulator approved in Lithuania and Portugal under the brand name Fablyn for the prevention and treatment of osteoporosis
Subscribe or to access all post and page content.